What is HoFH (Homozygous Familial Hypercholesterolemia)?
HoFH is a rare, life-threatening genetic disorder caused by biallelic mutations (typically in the LDLR gene) that result in markedly elevated LDL-cholesterol levels from birth, leading to accelerated atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, and premature death if untreated. 1
Genetic Basis and Pathophysiology
HoFH occurs when an individual inherits two defective copies of genes controlling LDL metabolism, most commonly the LDL receptor (LDLR) gene. This results in:
- Complete or near-complete loss of LDL receptor function, preventing normal clearance of LDL-cholesterol from the bloodstream 1
- Extreme LDL-cholesterol elevation from conception, with untreated levels typically around 500 mg/dL—approximately double those seen in heterozygous FH 2
- Prevalence of approximately 1 in 300,000 people, making it an ultra-rare condition 3
The severity varies based on residual LDLR activity, with biallelic null variants representing the most severe form 1.
Clinical Manifestations and Disease Burden
The hallmark of HoFH is premature and aggressive cardiovascular disease:
- ASCVD develops in childhood or adolescence, with myocardial infarction possible even in infancy for severe cases 4
- Supravalvular aortic stenosis can manifest in early childhood, significantly impairing quality of life 4
- 67.4% of real-world HoFH patients have established ASCVD, with 63.4% having coronary heart disease 5
- Patients require percutaneous and surgical cardiac interventions at significantly younger ages compared to heterozygous FH 2
Critical Diagnostic Considerations
HoFH is severely underdiagnosed and undertreated in the United States, with unacceptably high numbers remaining undiagnosed until after a major cardiovascular event 3. Key diagnostic features include:
- Untreated LDL-cholesterol levels typically >500 mg/dL (approximately double heterozygous FH levels) 2
- Genetic confirmation showing biallelic pathogenic variants in LDLR or other genes involved in LDL metabolism 6
- Physical examination findings may include tendon xanthomas and corneal arcus, though these develop over time
Screening Recommendations
The 2023 European Atherosclerosis Society Consensus Statement recommends broadening pediatric guidelines to include lipid screening of newborn infants for the first time, recognizing that HoFH complications manifest much earlier than heterozygous FH 3. This represents a paradigm shift, as current U.S. guidelines only recommend universal screening at ages 9-11, which is far too late for HoFH detection 3.
Treatment Urgency and Prognosis
Without aggressive early treatment, HoFH leads to premature death from cardiovascular complications. 1 The disease requires fundamentally different and stricter therapeutic strategies compared to heterozygous FH 2. Real-world data shows that despite recent therapeutic advances, 52.9% of patients remain on suboptimal therapy with mean LDL-cholesterol of 163 mg/dL—far above target levels 5.
The past three decades have seen major treatment advances that have improved ASCVD outcomes, but early diagnosis and immediate aggressive intervention remain critical to prevent irreversible cardiovascular damage 1.